JP2012502981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502981A5 JP2012502981A5 JP2011527466A JP2011527466A JP2012502981A5 JP 2012502981 A5 JP2012502981 A5 JP 2012502981A5 JP 2011527466 A JP2011527466 A JP 2011527466A JP 2011527466 A JP2011527466 A JP 2011527466A JP 2012502981 A5 JP2012502981 A5 JP 2012502981A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pyrazolo
- methyl
- pyridine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 29
- -1 substituted Chemical class 0.000 claims description 20
- 230000033115 angiogenesis Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 9
- 102000004722 NADPH Oxidases Human genes 0.000 claims description 7
- 108010002998 NADPH Oxidases Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 22
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 21
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- ICZVBOAABXHPSZ-UHFFFAOYSA-N piperidine-2,5-dione Chemical compound O=C1CCC(=O)NC1 ICZVBOAABXHPSZ-UHFFFAOYSA-N 0.000 claims 3
- GIVSZYOESAXKLC-UHFFFAOYSA-N 2,5-dihydro-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1NC=C2C(=O)NNC2=C1 GIVSZYOESAXKLC-UHFFFAOYSA-N 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000005229 pyrazolopyridines Chemical class 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KYXAVGBVNXUSPJ-UHFFFAOYSA-N 2,4-bis(3-chlorophenyl)-5-(3-hydroxypropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C=C(Cl)C=CC=2)C(=O)C=2C1=CC(=O)N(CCCO)C=2C1=CC=CC(Cl)=C1 KYXAVGBVNXUSPJ-UHFFFAOYSA-N 0.000 claims 1
- TYKNOHQECDBFFG-UHFFFAOYSA-N 2,4-dimethyl-5-(3-morpholin-4-yl-3-phenylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C)C(=O)C2=C(C)N1CCC(C=1C=CC=CC=1)N1CCOCC1 TYKNOHQECDBFFG-UHFFFAOYSA-N 0.000 claims 1
- REPLAUKRSYGQCF-UHFFFAOYSA-N 2,4-dimethyl-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 REPLAUKRSYGQCF-UHFFFAOYSA-N 0.000 claims 1
- KPQLXWBACSEAIY-UHFFFAOYSA-N 2,4-dimethyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 KPQLXWBACSEAIY-UHFFFAOYSA-N 0.000 claims 1
- UYRDYQVNBZUUFO-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)-4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C(=C(Cl)C=CC=2)Cl)C2=O)C2=C1C UYRDYQVNBZUUFO-UHFFFAOYSA-N 0.000 claims 1
- OQUPPCHOLDULTN-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=C(Cl)C=CC=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 OQUPPCHOLDULTN-UHFFFAOYSA-N 0.000 claims 1
- DTPIZSZOPZWOSD-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=C(Cl)C=3)Cl)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 DTPIZSZOPZWOSD-UHFFFAOYSA-N 0.000 claims 1
- KOAHEOQVOXWCEL-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=C(Cl)C=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 KOAHEOQVOXWCEL-UHFFFAOYSA-N 0.000 claims 1
- JSZBTGWTGLVHSN-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4,5-dimethyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C1=CC=C(F)C=C1Cl JSZBTGWTGLVHSN-UHFFFAOYSA-N 0.000 claims 1
- LMDLSVMPBUPEBS-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4-(methoxymethyl)-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC(F)=CC=3)Cl)C(=O)C2=C(COC)N1CC1=CC=CC=C1CN1CCOCC1 LMDLSVMPBUPEBS-UHFFFAOYSA-N 0.000 claims 1
- GKROQAQDYJPFCN-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC(F)=CC=3)Cl)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 GKROQAQDYJPFCN-UHFFFAOYSA-N 0.000 claims 1
- PRNBIEYRADGJCE-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C(=CC(F)=CC=2)Cl)C2=O)C2=C1C PRNBIEYRADGJCE-UHFFFAOYSA-N 0.000 claims 1
- WUBNGXBUNZLASY-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4-methyl-5-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C1=CC=CC=C1CN1C(=O)C=C(NN(C=2C(=CC(F)=CC=2)Cl)C2=O)C2=C1C WUBNGXBUNZLASY-UHFFFAOYSA-N 0.000 claims 1
- VQUDPYBOGYTBBR-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC(F)=CC=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 VQUDPYBOGYTBBR-UHFFFAOYSA-N 0.000 claims 1
- WRCYEDJLNSBZHE-UHFFFAOYSA-N 2-(2-chlorophenyl)-4,5-dimethyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C1=CC=CC=C1Cl WRCYEDJLNSBZHE-UHFFFAOYSA-N 0.000 claims 1
- KJQWOWLDTVSADY-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(2-fluorophenyl)-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C(=CC=CC=2)Cl)C(=O)C=2C1=CC(=O)N(C)C=2C1=CC=CC=C1F KJQWOWLDTVSADY-UHFFFAOYSA-N 0.000 claims 1
- RGMDYMOVLWNGGN-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-(3-ethoxypropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C(=CC=CC=2)Cl)C(=O)C=2C1=CC(=O)N(CCCOCC)C=2C1=CC=C(Cl)C=C1 RGMDYMOVLWNGGN-UHFFFAOYSA-N 0.000 claims 1
- VGEVTZMEMJTPCL-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-[3-(dimethylamino)propyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C(=CC=CC=2)Cl)C(=O)C=2C1=CC(=O)N(CCCN(C)C)C=2C1=CC=C(Cl)C=C1 VGEVTZMEMJTPCL-UHFFFAOYSA-N 0.000 claims 1
- ZGQGAMXRPSNGAM-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C(=CC=CC=2)Cl)C(=O)C=2C1=CC(=O)N(C)C=2C1=CC=C(Cl)C=C1 ZGQGAMXRPSNGAM-UHFFFAOYSA-N 0.000 claims 1
- KEKFTFDSCQLTLX-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 KEKFTFDSCQLTLX-UHFFFAOYSA-N 0.000 claims 1
- YRQQEMIXQLMLOU-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-phenylethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC(C=1C=CC=CC=1)N1CCOCC1 YRQQEMIXQLMLOU-UHFFFAOYSA-N 0.000 claims 1
- JINBUKAYMLVOMA-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-(3-phenylprop-2-ynyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC#CC1=CC=CC=C1 JINBUKAYMLVOMA-UHFFFAOYSA-N 0.000 claims 1
- XDQVGFASNAANGE-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[(2-morpholin-4-ylphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=C1N1CCOCC1 XDQVGFASNAANGE-UHFFFAOYSA-N 0.000 claims 1
- CIOUWNFQNIJKBV-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 CIOUWNFQNIJKBV-UHFFFAOYSA-N 0.000 claims 1
- YQYNWIFVDAIJMK-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[(6-morpholin-4-ylpyridin-2-yl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC(N=1)=CC=CC=1N1CCOCC1 YQYNWIFVDAIJMK-UHFFFAOYSA-N 0.000 claims 1
- YYWQXACDBDCTHO-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C(=CC=CC=2)Cl)C2=O)C2=C1C YYWQXACDBDCTHO-UHFFFAOYSA-N 0.000 claims 1
- RNGLVLSXXYCAHO-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 RNGLVLSXXYCAHO-UHFFFAOYSA-N 0.000 claims 1
- XKUPUTKAVAWLTM-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[[4-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC(C=C1)=CC=C1CN1CCOCC1 XKUPUTKAVAWLTM-UHFFFAOYSA-N 0.000 claims 1
- AFZWIYFEICOZIA-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1CN1C(=O)C=C(NN(C=2C(=CC=CC=2)Cl)C2=O)C2=C1C AFZWIYFEICOZIA-UHFFFAOYSA-N 0.000 claims 1
- RYGPVTKHNQSBNJ-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-(3-ethoxypropyl)-4-methyl-1-(pyridin-2-ylmethyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C(N2C=3C(=CC=CC=3)Cl)=O)C=1N2CC1=CC=CC=N1 RYGPVTKHNQSBNJ-UHFFFAOYSA-N 0.000 claims 1
- PDACJHUCRPPXGF-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-(3-ethoxypropyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C1=CC=CC=C1Cl PDACJHUCRPPXGF-UHFFFAOYSA-N 0.000 claims 1
- VQXIMZFSMHXQNT-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-(3-hydroxypropyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(CCCO)C(=O)C=C2NN1C1=CC=CC=C1Cl VQXIMZFSMHXQNT-UHFFFAOYSA-N 0.000 claims 1
- KRHOFJSKUFLUIO-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-(cyclohexylmethyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC1CCCCC1 KRHOFJSKUFLUIO-UHFFFAOYSA-N 0.000 claims 1
- IPOPWQARYBSNET-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=CN(CC=3C=C(OC=4C=CC=CC=4)C=CC=3)C(=O)C=C2N1 IPOPWQARYBSNET-UHFFFAOYSA-N 0.000 claims 1
- GZHXOZDAYYANSW-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[2-(3-methoxyphenyl)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound COC1=CC=CC(CCN2C(C=C3C(C(N(C=4C(=CC=CC=4)Cl)N3)=O)=C2C)=O)=C1 GZHXOZDAYYANSW-UHFFFAOYSA-N 0.000 claims 1
- RUKMPYVDWDEZDQ-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[2-(dimethylamino)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCN(C)C)C(C)=C(C2=O)C=1NN2C1=CC=CC=C1Cl RUKMPYVDWDEZDQ-UHFFFAOYSA-N 0.000 claims 1
- ABSJAYONOLGODP-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-methyl-4-(1-phenylmethoxyethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1C(C)OCC1=CC=CC=C1 ABSJAYONOLGODP-UHFFFAOYSA-N 0.000 claims 1
- IDDDKICSEMITDK-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-methyl-4-(3-morpholin-4-ylphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C(=CC=CC=2)Cl)C(=O)C=2C1=CC(=O)N(C)C=2C(C=1)=CC=CC=1N1CCOCC1 IDDDKICSEMITDK-UHFFFAOYSA-N 0.000 claims 1
- SJZNHPLAJCICKZ-UHFFFAOYSA-N 2-(2-fluorophenyl)-4,5-dimethyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C1=CC=CC=C1F SJZNHPLAJCICKZ-UHFFFAOYSA-N 0.000 claims 1
- DKVPFWLNGSWTND-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-methyl-5-(3-morpholin-4-yl-3-phenylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)F)C(=O)C2=C(C)N1CCC(C=1C=CC=CC=1)N1CCOCC1 DKVPFWLNGSWTND-UHFFFAOYSA-N 0.000 claims 1
- GFFYZUHBVIAMMS-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-methyl-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)F)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 GFFYZUHBVIAMMS-UHFFFAOYSA-N 0.000 claims 1
- QXJZRUHEWOGCFI-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-methyl-5-[(6-morpholin-4-ylpyridin-2-yl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)F)C(=O)C2=C(C)N1CC(N=1)=CC=CC=1N1CCOCC1 QXJZRUHEWOGCFI-UHFFFAOYSA-N 0.000 claims 1
- QPOQXQSXCVPJMM-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)F)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 QPOQXQSXCVPJMM-UHFFFAOYSA-N 0.000 claims 1
- MBSAOSFODAJFMF-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-methyl-5-[[4-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)F)C(=O)C2=C(C)N1CC(C=C1)=CC=C1CN1CCOCC1 MBSAOSFODAJFMF-UHFFFAOYSA-N 0.000 claims 1
- NTSBUCZLOJODHN-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(Cl)=CC=3)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 NTSBUCZLOJODHN-UHFFFAOYSA-N 0.000 claims 1
- QIIPZLZLKZSPEE-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(Cl)=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 QIIPZLZLKZSPEE-UHFFFAOYSA-N 0.000 claims 1
- JSEIKVVNTNKSKZ-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(F)=CC=3)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 JSEIKVVNTNKSKZ-UHFFFAOYSA-N 0.000 claims 1
- MJVGZISBTBDQBK-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C=C(Cl)C(F)=CC=2)C2=O)C2=C1C MJVGZISBTBDQBK-UHFFFAOYSA-N 0.000 claims 1
- LKXRLZXVDQIXNT-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(F)=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 LKXRLZXVDQIXNT-UHFFFAOYSA-N 0.000 claims 1
- MGDPZHRLRLDUKS-UHFFFAOYSA-N 2-(3-chlorophenyl)-4,5-dimethyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C1=CC=CC(Cl)=C1 MGDPZHRLRLDUKS-UHFFFAOYSA-N 0.000 claims 1
- BFGGBCLYTBRSFU-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-(3-morpholin-4-yl-3-phenylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C=CC=3)C(=O)C2=C(C)N1CCC(C=1C=CC=CC=1)N1CCOCC1 BFGGBCLYTBRSFU-UHFFFAOYSA-N 0.000 claims 1
- XUTIKTNOMQXOSN-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-(3-phenylprop-2-ynyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C=CC=3)C(=O)C2=C(C)N1CC#CC1=CC=CC=C1 XUTIKTNOMQXOSN-UHFFFAOYSA-N 0.000 claims 1
- MDXAJEVSXQMDGG-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C=CC=3)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 MDXAJEVSXQMDGG-UHFFFAOYSA-N 0.000 claims 1
- ICDFAHCPGGLTGC-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C=C(Cl)C=CC=2)C2=O)C2=C1C ICDFAHCPGGLTGC-UHFFFAOYSA-N 0.000 claims 1
- JISUACJETHHGLR-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C1=CC=CC=C1CN1C(=O)C=C(NN(C=2C=C(Cl)C=CC=2)C2=O)C2=C1C JISUACJETHHGLR-UHFFFAOYSA-N 0.000 claims 1
- CQQAAYFZFHEBHG-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 CQQAAYFZFHEBHG-UHFFFAOYSA-N 0.000 claims 1
- SUHBZPQRROPTCA-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-methyl-5-[[4-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C=CC=3)C(=O)C2=C(C)N1CC(C=C1)=CC=C1CN1CCOCC1 SUHBZPQRROPTCA-UHFFFAOYSA-N 0.000 claims 1
- OVIMLCPHYLGLHN-UHFFFAOYSA-N 2-(3-chlorophenyl)-5-(3-ethoxypropyl)-4-[(3-methoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C=2C=C(Cl)C=CC=2)C(=O)C=2C1=CC(=O)N(CCCOCC)C=2CC1=CC=CC(OC)=C1 OVIMLCPHYLGLHN-UHFFFAOYSA-N 0.000 claims 1
- OKGIZSKZGDRQMC-UHFFFAOYSA-N 2-(3-chlorophenyl)-5-(3-ethoxypropyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C1=CC=CC(Cl)=C1 OKGIZSKZGDRQMC-UHFFFAOYSA-N 0.000 claims 1
- WQYYVJULEXPLFE-UHFFFAOYSA-N 2-(3-chlorophenyl)-5-(3-hydroxypropyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(CCCO)C(=O)C=C2NN1C1=CC=CC(Cl)=C1 WQYYVJULEXPLFE-UHFFFAOYSA-N 0.000 claims 1
- IQZMDBRTWJWXHB-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-methyl-5-[(3-phenoxyphenyl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(Cl)=CC=3)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 IQZMDBRTWJWXHB-UHFFFAOYSA-N 0.000 claims 1
- AVDFSDMABZKRKG-UHFFFAOYSA-N 2-benzyl-4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(CC=3C=CC=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 AVDFSDMABZKRKG-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- VIQRCDZBQUYVOS-UHFFFAOYSA-N 3-(4,5-dimethyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-2-yl)benzonitrile Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C1=CC=CC(C#N)=C1 VIQRCDZBQUYVOS-UHFFFAOYSA-N 0.000 claims 1
- OCANGOKECPUXDO-UHFFFAOYSA-N 3-[4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-2-yl]benzonitrile Chemical compound O=C1C=C2NN(C=3C=C(C=CC=3)C#N)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 OCANGOKECPUXDO-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- IVVYYDQEOSJUJU-UHFFFAOYSA-N 4,5-dimethyl-2-(4-phenyl-1,3-thiazol-2-yl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C(SC=1)=NC=1C1=CC=CC=C1 IVVYYDQEOSJUJU-UHFFFAOYSA-N 0.000 claims 1
- LVJKSDPRUUJIPK-UHFFFAOYSA-N 4,5-dimethyl-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(C)C(=O)C=C2NN1C(C=C1)=CC=C1OCC1=CC=CC=C1 LVJKSDPRUUJIPK-UHFFFAOYSA-N 0.000 claims 1
- RTHIKBFTYSTIHR-UHFFFAOYSA-N 4,5-dimethyl-2-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(N2C(C3=C(C)N(C)C(=O)C=C3N2)=O)N=C1 RTHIKBFTYSTIHR-UHFFFAOYSA-N 0.000 claims 1
- ZZFDZTOMYIXPFZ-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC(Cl)=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(=O)N1CCOCC1 ZZFDZTOMYIXPFZ-UHFFFAOYSA-N 0.000 claims 1
- WEECQLQVRZXROS-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-5-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CN1C(=O)C=C(NN(C)C2=O)C2=C1C1=CC=CC(Cl)=C1 WEECQLQVRZXROS-UHFFFAOYSA-N 0.000 claims 1
- GGWPJZDUPMYUMU-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC(Cl)=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC1=CC=CC=C1CN1CCOCC1 GGWPJZDUPMYUMU-UHFFFAOYSA-N 0.000 claims 1
- IRXGBBHHXPXYRS-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-5-[[3-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC(Cl)=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(C=1)=CC=CC=1CN1CCOCC1 IRXGBBHHXPXYRS-UHFFFAOYSA-N 0.000 claims 1
- OYAVHVOKBUTVAZ-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-5-[[4-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC(Cl)=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(C=C1)=CC=C1CN1CCOCC1 OYAVHVOKBUTVAZ-UHFFFAOYSA-N 0.000 claims 1
- DHXPNTXSSCKCEA-UHFFFAOYSA-N 4-(3-chlorophenyl)-5-(3-ethoxypropyl)-2-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C)C(=O)C=2C1=CC(=O)N(CCCOCC)C=2C1=CC=CC(Cl)=C1 DHXPNTXSSCKCEA-UHFFFAOYSA-N 0.000 claims 1
- KRXLVAAQZGFKRC-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-methyl-5-[(6-morpholin-4-ylpyridin-2-yl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=C(Cl)C=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(N=1)=CC=CC=1N1CCOCC1 KRXLVAAQZGFKRC-UHFFFAOYSA-N 0.000 claims 1
- XLMBOFVFNUEDSO-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-methyl-5-[(6-pyrrolidin-1-ylpyridin-2-yl)methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=C(Cl)C=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(N=1)=CC=CC=1N1CCCC1 XLMBOFVFNUEDSO-UHFFFAOYSA-N 0.000 claims 1
- XDFLPNVFWHNHBI-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-methyl-5-[[4-(morpholin-4-ylmethyl)phenyl]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=C(Cl)C=CC=1C1=C2C(=O)N(C)NC2=CC(=O)N1CC(C=C1)=CC=C1CN1CCOCC1 XDFLPNVFWHNHBI-UHFFFAOYSA-N 0.000 claims 1
- NXWNELYKNPAIPW-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-(3-ethoxypropyl)-2-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound N1N(C)C(=O)C=2C1=CC(=O)N(CCCOCC)C=2C1=CC=C(Cl)C=C1 NXWNELYKNPAIPW-UHFFFAOYSA-N 0.000 claims 1
- QQGQQESYRBCASL-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-[[3-(dimethylamino)phenyl]methyl]-2-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CN(C)C1=CC=CC(CN2C(C=C3C(C(N(C)N3)=O)=C2C=2C=CC(Cl)=CC=2)=O)=C1 QQGQQESYRBCASL-UHFFFAOYSA-N 0.000 claims 1
- YRPTWKSWTNFNFE-UHFFFAOYSA-N 4-[3-(dimethylamino)phenyl]-2-(2-methoxyphenyl)-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound COC1=CC=CC=C1N1C(=O)C2=C(C=3C=C(C=CC=3)N(C)C)N(C)C(=O)C=C2N1 YRPTWKSWTNFNFE-UHFFFAOYSA-N 0.000 claims 1
- SPVJQXLGAIFMGF-UHFFFAOYSA-N 4-fluoro-n-[2-[4-methyl-3,6-dioxo-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridin-5-yl]ethyl]benzamide Chemical compound O=C1C=C2NN(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C(=O)C2=C(C)N1CCNC(=O)C1=CC=C(F)C=C1 SPVJQXLGAIFMGF-UHFFFAOYSA-N 0.000 claims 1
- BDOMGTISRGWHSE-UHFFFAOYSA-N 4-methyl-5-(2-morpholin-4-yl-2-oxoethyl)-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C(=O)C2=C(C)N1CC(=O)N1CCOCC1 BDOMGTISRGWHSE-UHFFFAOYSA-N 0.000 claims 1
- RYSBUWINJZTDHX-UHFFFAOYSA-N 4-methyl-5-[(3-phenoxyphenyl)methyl]-2-(4-phenyl-1,3-thiazol-2-yl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC=C(N=3)C=3C=CC=CC=3)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 RYSBUWINJZTDHX-UHFFFAOYSA-N 0.000 claims 1
- HBDSBWKHUPDBFU-UHFFFAOYSA-N 4-methyl-5-[(3-phenoxyphenyl)methyl]-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 HBDSBWKHUPDBFU-UHFFFAOYSA-N 0.000 claims 1
- BOYPOQAOJLYGIL-UHFFFAOYSA-N 4-methyl-5-[(3-phenoxyphenyl)methyl]-2-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C3=NN4C=NN=C4C=C3)C(=O)C2=C(C)N1CC(C=1)=CC=CC=1OC1=CC=CC=C1 BOYPOQAOJLYGIL-UHFFFAOYSA-N 0.000 claims 1
- LVEUPZBOIWRPGM-UHFFFAOYSA-N 4-methyl-5-[4-(4-methylpiperazin-1-yl)-4-oxobutyl]-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C)CCN1C(=O)CCCN1C(=O)C=C(NN(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C2=O)C2=C1C LVEUPZBOIWRPGM-UHFFFAOYSA-N 0.000 claims 1
- DHMTWSKIDXQSBY-UHFFFAOYSA-N 4-methyl-5-[[2-(morpholin-4-ylmethyl)phenyl]methyl]-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1CN1CCOCC1 DHMTWSKIDXQSBY-UHFFFAOYSA-N 0.000 claims 1
- CDTGYGTXQVKWRX-UHFFFAOYSA-N 5-(3-ethoxypropyl)-2-(2-fluorophenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C1=CC=CC=C1F CDTGYGTXQVKWRX-UHFFFAOYSA-N 0.000 claims 1
- ZCIZFSXWBXKCFQ-UHFFFAOYSA-N 5-(3-ethoxypropyl)-4-methyl-2-(2-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C1=CC=CC=C1OCC1=CC=CC=C1 ZCIZFSXWBXKCFQ-UHFFFAOYSA-N 0.000 claims 1
- HXQMSKGSKNJJLB-UHFFFAOYSA-N 5-(3-ethoxypropyl)-4-methyl-2-(4-phenyl-1,3-thiazol-2-yl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C(SC=1)=NC=1C1=CC=CC=C1 HXQMSKGSKNJJLB-UHFFFAOYSA-N 0.000 claims 1
- YLRQBKGTXREGKV-UHFFFAOYSA-N 5-(3-ethoxypropyl)-4-methyl-2-(4-phenylmethoxyphenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C(C=C1)=CC=C1OCC1=CC=CC=C1 YLRQBKGTXREGKV-UHFFFAOYSA-N 0.000 claims 1
- JEUKQKWTCQKOJR-UHFFFAOYSA-N 5-[2-(4-benzylpiperazin-1-yl)-2-oxoethyl]-2-(2,5-dichlorophenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=C(Cl)C=3)Cl)C(=O)C2=C(C)N1CC(=O)N(CC1)CCN1CC1=CC=CC=C1 JEUKQKWTCQKOJR-UHFFFAOYSA-N 0.000 claims 1
- ASSQHCYYWDBHBC-UHFFFAOYSA-N 5-[2-(4-benzylpiperazin-1-yl)-2-oxoethyl]-2-(2-chloro-4-fluorophenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC(F)=CC=3)Cl)C(=O)C2=C(C)N1CC(=O)N(CC1)CCN1CC1=CC=CC=C1 ASSQHCYYWDBHBC-UHFFFAOYSA-N 0.000 claims 1
- PZVYFQWLAFCPTH-UHFFFAOYSA-N 5-[2-(4-benzylpiperazin-1-yl)-2-oxoethyl]-2-(3-chloro-4-fluorophenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(F)=CC=3)C(=O)C2=C(C)N1CC(=O)N(CC1)CCN1CC1=CC=CC=C1 PZVYFQWLAFCPTH-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- YKPBHPWMRQNCGC-UHFFFAOYSA-N ClC1=C(C=CC=C1)N1NC=2C(=C(N(C(C2)=O)CCCN(C)C)C)C1=O Chemical compound ClC1=C(C=CC=C1)N1NC=2C(=C(N(C(C2)=O)CCCN(C)C)C)C1=O YKPBHPWMRQNCGC-UHFFFAOYSA-N 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- ACOHAEBNFWGQCL-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CC=N1 ACOHAEBNFWGQCL-UHFFFAOYSA-N 0.000 claims 1
- DGFBNVQHSDTYAX-UHFFFAOYSA-N n-[2-[2-(2,5-dichlorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]ethyl]acetamide Chemical compound C=1C(=O)N(CCNC(=O)C)C(C)=C(C2=O)C=1NN2C1=CC(Cl)=CC=C1Cl DGFBNVQHSDTYAX-UHFFFAOYSA-N 0.000 claims 1
- ONIHHGXDRFKBKC-UHFFFAOYSA-N n-[2-[2-(2-chloro-4-fluorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]ethyl]-4-fluorobenzamide Chemical compound O=C1C=C2NN(C=3C(=CC(F)=CC=3)Cl)C(=O)C2=C(C)N1CCNC(=O)C1=CC=C(F)C=C1 ONIHHGXDRFKBKC-UHFFFAOYSA-N 0.000 claims 1
- BFTPZCCGJJFSAS-UHFFFAOYSA-N n-[2-[2-(3-chloro-4-fluorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]ethyl]-4-fluorobenzamide Chemical compound O=C1C=C2NN(C=3C=C(Cl)C(F)=CC=3)C(=O)C2=C(C)N1CCNC(=O)C1=CC=C(F)C=C1 BFTPZCCGJJFSAS-UHFFFAOYSA-N 0.000 claims 1
- KATUAIBHOJWLQG-UHFFFAOYSA-N n-[2-[4-(4-chlorophenyl)-2-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]ethyl]acetamide Chemical compound N1N(C)C(=O)C=2C1=CC(=O)N(CCNC(=O)C)C=2C1=CC=C(Cl)C=C1 KATUAIBHOJWLQG-UHFFFAOYSA-N 0.000 claims 1
- MGUDPRMCKVXORJ-UHFFFAOYSA-N n-[3-[2-(2,3-dichlorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(C=C3C(C(N(C=4C(=C(Cl)C=CC=4)Cl)N3)=O)=C2C)=O)=C1 MGUDPRMCKVXORJ-UHFFFAOYSA-N 0.000 claims 1
- DRLRHQHNTVMRHL-UHFFFAOYSA-N n-[3-[2-(2-chloro-4-fluorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(C=C3C(C(N(C=4C(=CC(F)=CC=4)Cl)N3)=O)=C2C)=O)=C1 DRLRHQHNTVMRHL-UHFFFAOYSA-N 0.000 claims 1
- HYKMIXLFSLZZAG-UHFFFAOYSA-N n-[3-[2-(3-chloro-4-fluorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(C=C3C(C(N(C=4C=C(Cl)C(F)=CC=4)N3)=O)=C2C)=O)=C1 HYKMIXLFSLZZAG-UHFFFAOYSA-N 0.000 claims 1
- YFKSKTUWFOUTAX-UHFFFAOYSA-N n-[3-[5-(3-ethoxypropyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-2-yl]phenyl]acetamide Chemical compound C=1C(=O)N(CCCOCC)C(C)=C(C2=O)C=1NN2C1=CC=CC(NC(C)=O)=C1 YFKSKTUWFOUTAX-UHFFFAOYSA-N 0.000 claims 1
- NRILBWUBJDPDPM-UHFFFAOYSA-N n-[3-[[2-(3-chloro-4-fluorophenyl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]methyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(CN2C(C=C3C(C(N(C=4C=C(Cl)C(F)=CC=4)N3)=O)=C2C)=O)=C1 NRILBWUBJDPDPM-UHFFFAOYSA-N 0.000 claims 1
- XCVGEPAWPWANGP-UHFFFAOYSA-N n-[3-[[4-(3-chlorophenyl)-2-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]methyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(CN2C(C=C3C(C(N(C)N3)=O)=C2C=2C=C(Cl)C=CC=2)=O)=C1 XCVGEPAWPWANGP-UHFFFAOYSA-N 0.000 claims 1
- RVQCJNROYARBEX-UHFFFAOYSA-N n-[3-[[4-(4-chlorophenyl)-2-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]methyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(CN2C(C=C3C(C(N(C)N3)=O)=C2C=2C=CC(Cl)=CC=2)=O)=C1 RVQCJNROYARBEX-UHFFFAOYSA-N 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- RGYQPQARIQKJKH-UHFFFAOYSA-N setanaxib Chemical compound CN(C)C1=CC=CC(C2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2C)=C1 RGYQPQARIQKJKH-UHFFFAOYSA-N 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 description 18
- 208000016192 Demyelinating disease Diseases 0.000 description 7
- 206010012305 Demyelination Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 206010006451 bronchitis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 0 CC(*N)=C(C(C(C(ON)=O)N)=**1N)C1=O Chemical compound CC(*N)=C(C(C(C(ON)=O)N)=**1N)C1=O 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003256 Arthritis gonococcal Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 201000009084 Dysgammaglobulinemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010020877 Hypertrophic osteoarthropathy Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 206010036626 Presbyacusis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047097 Vascular purpura Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002664 drug-induced hearing loss Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000011201 multicentric reticulohistiocytosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000007321 sebaceous carcinoma Diseases 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003839 sprouting angiogenesis Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164857A EP2166010A1 (en) | 2008-09-23 | 2008-09-23 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP08164857.8 | 2008-09-23 | ||
| PCT/IB2009/054156 WO2010035221A1 (en) | 2008-09-23 | 2009-09-22 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014254651A Division JP5932008B2 (ja) | 2008-09-23 | 2014-12-17 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含む医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502981A JP2012502981A (ja) | 2012-02-02 |
| JP2012502981A5 true JP2012502981A5 (enExample) | 2012-11-08 |
| JP5700837B2 JP5700837B2 (ja) | 2015-04-15 |
Family
ID=40328866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527466A Active JP5700837B2 (ja) | 2008-09-23 | 2009-09-22 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体 |
| JP2014254651A Active JP5932008B2 (ja) | 2008-09-23 | 2014-12-17 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含む医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014254651A Active JP5932008B2 (ja) | 2008-09-23 | 2014-12-17 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含む医薬製剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9096588B2 (enExample) |
| EP (3) | EP2166010A1 (enExample) |
| JP (2) | JP5700837B2 (enExample) |
| KR (3) | KR101789479B1 (enExample) |
| CN (1) | CN102159573B (enExample) |
| AU (1) | AU2009298008B2 (enExample) |
| BR (1) | BRPI0919330A2 (enExample) |
| CA (1) | CA2737550C (enExample) |
| CY (1) | CY1115952T1 (enExample) |
| DK (2) | DK2860179T3 (enExample) |
| ES (2) | ES2528096T3 (enExample) |
| HR (1) | HRP20150082T1 (enExample) |
| IL (1) | IL211892A0 (enExample) |
| PL (2) | PL2344492T3 (enExample) |
| PT (2) | PT2860179T (enExample) |
| RS (1) | RS53781B1 (enExample) |
| RU (1) | RU2538041C2 (enExample) |
| SI (1) | SI2344492T1 (enExample) |
| SM (1) | SMT201500070B (enExample) |
| TR (1) | TR201808380T4 (enExample) |
| WO (1) | WO2010035221A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| WO2012170752A1 (en) * | 2011-06-10 | 2012-12-13 | Glaxo Wellcome Manufacturing Pte Ltd | Novel compounds |
| EP2591782A1 (en) * | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
| CA2889029A1 (en) | 2012-10-24 | 2014-05-01 | Glucox Biotech Ab | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase |
| EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
| US10173988B2 (en) | 2015-02-16 | 2019-01-08 | Glucox Biotech Ab | N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
| US10906899B2 (en) | 2016-05-10 | 2021-02-02 | Georgia State University Research Foundation, Inc. | Bicyclic fused pyrazole derivatives for the treatment of RSV |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| KR20230038807A (ko) | 2016-09-09 | 2023-03-21 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암의 치료를 위한 이의 용도 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018049152A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AU2018262528A1 (en) | 2017-05-04 | 2019-11-21 | Glenmark Pharmaceuticals S.A. | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors |
| WO2019028877A1 (zh) * | 2017-08-11 | 2019-02-14 | 邦泰生物工程(深圳)有限公司 | 一种含有nadh和nadph的组合物及其应用 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| MX2020005029A (es) * | 2017-11-15 | 2020-08-13 | Univ Vanderbilt | Metodos y composiciones para el mejoramiento de la funcion lisosomal y tratamiento de enfermedad neurodegenerativa. |
| SMT202200294T1 (it) | 2018-02-20 | 2022-11-18 | Incyte Corp | Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| EP3946297A4 (en) | 2019-04-01 | 2023-08-02 | Emory University | HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASE INHIBITORS AND THEIR USES IN THE TREATMENT OF CANCER |
| BR112021024310A2 (pt) | 2019-06-05 | 2022-02-15 | Univ Emory | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus |
| TWI865579B (zh) | 2019-08-06 | 2024-12-11 | 美商英塞特公司 | Ｈｐｋ１抑制劑之固體形式 |
| CN115989060B (zh) * | 2020-08-28 | 2025-10-17 | 赛罗斯生物科技 | 新型硫代乙内酰脲衍生物及其用途 |
| US20240352013A1 (en) * | 2021-08-13 | 2024-10-24 | Georgia State University Research Foundation, Inc. | Bicyclic fused pyrazole derivatives for the treatment of respiratory infections including rsv |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| WO2023217764A1 (en) | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391407A (en) | 1966-08-15 | 1968-07-09 | William A. Waters | Helmet |
| US3931407A (en) | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
| DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
| DE19518082A1 (de) * | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| WO1998037068A1 (en) | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| EP1396493A4 (en) | 2001-04-26 | 2005-08-03 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS |
| EP1291017A3 (en) | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
| US7662826B2 (en) * | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| AU2003267980A1 (en) | 2002-07-03 | 2004-01-23 | Janssen Pharmaceutica, N.V. | Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders |
| NZ542059A (en) | 2003-02-28 | 2009-11-27 | Florey Howard Inst | Therapeutic compositions comprising an aryl sulphonate such as suramin, for the treatment of a pathological condition or event of the systemic vasculature resulting form the producation of reactive oxygen species. |
| WO2004089412A1 (ja) | 2003-04-08 | 2004-10-21 | Mitsubishi Pharma Corporation | 特異的ｎａｄ(ｐ)ｈオキシダーゼ抑制剤 |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| EP1809601B1 (en) | 2004-10-04 | 2014-09-10 | Manfredi, John | Compounds for alzheimer's disease |
| FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US20070014739A1 (en) * | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| US20080076778A1 (en) * | 2006-09-05 | 2008-03-27 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| EP3111933B1 (en) * | 2006-11-13 | 2019-09-04 | PCB Associates, Inc. | Prophylaxis or treatment of glomerulosclerosis |
| EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| AR069526A1 (es) | 2007-12-03 | 2010-01-27 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| US20090163452A1 (en) | 2007-12-20 | 2009-06-25 | Schwartz Janice B | Compositions and methods for lowering serum cholesterol |
| FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| WO2010059689A2 (en) * | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Rsv f vlps and methods of manufacture and use thereof |
| US8283002B2 (en) * | 2008-11-18 | 2012-10-09 | Plextronics, Inc. | Aminobenzene compositions and related devices and methods |
| BRPI0921509A2 (pt) * | 2008-11-19 | 2016-03-08 | Vertex Pharma | inibidor triazolotiadiazol de proteína quinase c-met |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP2521453B1 (en) | 2010-01-08 | 2016-05-11 | Beth Israel Deaconess Medical Center | Combinations of vitamin d and a statin for the treatment of migraine headaches |
| EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| CN102014373B (zh) | 2010-11-22 | 2015-04-01 | 中兴通讯股份有限公司 | 一种激活配置的方法及装置 |
| EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
-
2008
- 2008-09-23 EP EP08164857A patent/EP2166010A1/en not_active Withdrawn
-
2009
- 2009-09-22 JP JP2011527466A patent/JP5700837B2/ja active Active
- 2009-09-22 DK DK14190340.1T patent/DK2860179T3/en active
- 2009-09-22 US US13/120,440 patent/US9096588B2/en active Active
- 2009-09-22 KR KR1020177005530A patent/KR101789479B1/ko active Active
- 2009-09-22 PT PT141903401T patent/PT2860179T/pt unknown
- 2009-09-22 BR BRPI0919330A patent/BRPI0919330A2/pt not_active Application Discontinuation
- 2009-09-22 PL PL09787271T patent/PL2344492T3/pl unknown
- 2009-09-22 KR KR1020117006134A patent/KR20110056387A/ko not_active Ceased
- 2009-09-22 CN CN200980136710.4A patent/CN102159573B/zh active Active
- 2009-09-22 HR HRP20150082AT patent/HRP20150082T1/hr unknown
- 2009-09-22 WO PCT/IB2009/054156 patent/WO2010035221A1/en not_active Ceased
- 2009-09-22 TR TR2018/08380T patent/TR201808380T4/tr unknown
- 2009-09-22 KR KR1020167033919A patent/KR101763096B1/ko active Active
- 2009-09-22 PT PT97872717T patent/PT2344492E/pt unknown
- 2009-09-22 RS RS20150070A patent/RS53781B1/sr unknown
- 2009-09-22 RU RU2011116230/04A patent/RU2538041C2/ru active
- 2009-09-22 EP EP09787271.7A patent/EP2344492B1/en active Active
- 2009-09-22 EP EP14190340.1A patent/EP2860179B1/en active Active
- 2009-09-22 CA CA2737550A patent/CA2737550C/en active Active
- 2009-09-22 ES ES09787271.7T patent/ES2528096T3/es active Active
- 2009-09-22 DK DK09787271.7T patent/DK2344492T3/en active
- 2009-09-22 SI SI200931112T patent/SI2344492T1/sl unknown
- 2009-09-22 ES ES14190340.1T patent/ES2673405T3/es active Active
- 2009-09-22 AU AU2009298008A patent/AU2009298008B2/en active Active
- 2009-09-22 PL PL14190340T patent/PL2860179T3/pl unknown
-
2011
- 2011-03-23 IL IL211892A patent/IL211892A0/en active IP Right Grant
-
2014
- 2014-12-17 JP JP2014254651A patent/JP5932008B2/ja active Active
-
2015
- 2015-01-22 CY CY20151100063T patent/CY1115952T1/el unknown
- 2015-03-18 SM SM201500070T patent/SMT201500070B/xx unknown
- 2015-06-25 US US14/750,019 patent/US9974791B2/en active Active
-
2018
- 2018-04-23 US US15/959,318 patent/US10772891B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502981A5 (enExample) | ||
| JP2012502979A5 (enExample) | ||
| JP2012502980A5 (enExample) | ||
| JP2012502978A5 (enExample) | ||
| US10772891B2 (en) | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | |
| RU2640862C2 (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| CN102137862B (zh) | 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物 | |
| US8940760B2 (en) | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | |
| CN102209540A (zh) | 使用α7-选择性配体的治疗方法 | |
| JP2011504499A (ja) | トリプターゼ阻害剤として使用するためのスピロピペリジン | |
| AU2009260060B2 (en) | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them | |
| WO2011100359A1 (en) | Cannabinoid agonists | |
| WO2005063241A1 (ja) | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 | |
| JP2023511302A (ja) | 新規なピラゾール誘導体 | |
| JP5473598B2 (ja) | トリアジン誘導体の新規な医学的使用 | |
| US7741350B1 (en) | Bicyclic pyrazolo-heterocycles | |
| TW201808269A (zh) | 用於治療搔癢症及／或發癢之方法 | |
| CN115867277B (zh) | 新型稠合杂环基-碳腙酰二腈化合物及其用途 | |
| HK1159107B (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | |
| HK1160802A (en) | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | |
| HK1159092B (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |